India is home to nearly 90 million people with T2DM , with an estimated 39.4 million remaining undiagnosed. Recent estimates from India indicate that approximately 80% of individuals with T2DM ...
Background Metabolic-associated steatotic liver disease (MASLD) is a prevalent chronic liver disease affecting approximately ...
Objective To estimate the prevalence of potential overtreatment of type 2 diabetes mellitus (T2DM) among older adults and to develop and compare predictive models to identify patient and physician ...
India's diabetes burden has risen markedly, with 101 million individuals living with diabetes1. The clinical burden is ...
Physical activity programmes such as the NSC can help mitigate rising obesity and T2DM prevalence when implemented at the population level, as seen in Singapore. However, their success depends on ...
New ACC/AHA guidelines provide updated recommendations for dyslipidemia management, focusing on atherogenic lipoproteins and risk assessment.
1don MSN
Combination treatment benefits patients with advanced breast cancer that has spread to the brain
Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted ...
A GIP/GLP-1/glucagon triple agonist reduced HbA1c by up to 1.9 percentage points at 40 weeks for adults with type 2 diabetes, according to topline results from the TRANSCEND-T2D-1 trial. Retatrutide ...
Tirzepatide provided a larger reduction in HbA1c and greater improvements in multiple cardiometabolic parameters compared with conventional care for adults recently diagnosed with type 2 diabetes, ...
A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature ...
Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...
Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss—No Target Is Out of the Realm of Possibility Bispecific antibodies (bsAbs) have emerged as a novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results